The metalloproteinase ADAMTS1: A comprehensive review of its role in tumorigenic and metastatic pathways

International Journal of Cancer

Volumn 133, Issue 10, 2013, Pages 2263-2276

  De Arao Tan, Izza ^a   Ricciardelli, Carmela ^a   Russell, Darryl L ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

ADAMTS1; cancer; metalloproteinase; metastasis; pathways

Indexed keywords

ADAMTS1 PROTEIN; DNA; MESSENGER RNA; VASCULOTROPIN;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; DNA METHYLATION; EXTRACELLULAR MATRIX; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; METASTASIS POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION;

ADAMTS1; CANCER; METALLOPROTEINASE; METASTASIS; PATHWAYS;

ADAM PROTEINS; ANIMALS; CARCINOGENESIS; HUMANS; METALLOPROTEASES; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION;

EID: 84883763955     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28127     Document Type: Review

References (164)

1. Koblinski J, Ahram M, Sloane B,. Unraveling the role of proteases in cancer. Clin Chim Acta 2000; 291: 113-35.
2. Rucci N, Sanità P, Angelucci A,. Roles of metalloproteases in metastatic niche. Curr Mol Med 2011; 11: 609-22.
3. Kumar S, Sharghi-Namini S, Rao N, et al. ADAMTS5 Functions as an Anti-Angiogenic and Anti-Tumorigenic Protein Independent of Its Proteoglycanase Activity. Am J Pathol 2012; 181: 1056-68.
4. Wang D, Zhu T, Zhang FB, He C,. Expression of ADAMTS12 in colorectal cancer-associated stroma prevents cancer development and is a good prognostic indicator of colorectal cancer. Digest Dis Sci 2011; 56: 3281-7.
5. Molokwu CN, Adeniji OO, Chandrasekharan S, et al. Androgen regulates ADAMTS15 gene expression in prostate cancer cells. Cancer Invest 2010; 28: 698-710.
6. Porter S, Span PN, Sweep FC, et al. ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma. Int J Cancer 2006; 118: 1241-7.
7. Viloria CG, Obaya AJ, Moncada-Pazos A, et al. Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer. Cancer Res 2009; 69: 4926-34.
8. Lo PH, Lung HL, Cheung AK, et al. Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis. Cancer Res 2010; 70: 5567-76.
9. El Hour M, Moncada-Pazos A, Blacher S, et al. Higher sensitivity of Adamts12-deficient mice to tumor growth and angiogenesis. Oncogene 2010; 29: 3025-32.
10. Llamazares M, Obaya AJ, Moncada-Pazos A, et al. The ADAMTS12 metalloproteinase exhibits anti-tumorigenic properties through modulation of the Ras-dependent ERK signalling pathway. J Cell Sci 2007; 120: 3544-52.
11. Demircan K, Gunduz E, Gunduz M, et al. Increased mRNA expression of ADAMTS metalloproteinases in metastatic foci of head and neck cancer. Head Neck 2009; 31: 793-801.
12. Okada Y,. Tumor cell-matrix interaction: pericellular matrix degradation and metastasis. Verhandlungen der Deutschen Gesellschaft fur Pathol 2000; 84: 33-75.
13. Cross NA, Chandrasekharan S, Jokonya N, et al. The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican. Prostate 2005; 63: 269-75.
14. Ricciardelli C, Frewin KM, Tan Ide A, et al. The ADAMTS1 protease gene is required for mammary tumor growth and metastasis. Am J Pathol 2011; 179: 3075-85.
15. Porter S, Clark IM, Kevorkian L, et al. The ADAMTS metalloproteinases. Biochem J 2005; 386: 15-27.
16. Kuno K, Iizasa H, Ohno S, et al. The exon/intron organization and chromosomal mapping of the mouse ADAMTS-1 gene encoding an ADAM family protein with TSP motifs. Genomics 1997; 46: 466-71.
17. Kuno K, Matsushima K,. ADAMTS-1 protein anchors at the extracellular matrix through the thrombospondin type I motifs and its spacing region. J Biol Chem 1998; 273: 13912-7.
18. Colige A, Vandenberghe I, Thiry M, et al. Cloning and characterization of ADAMTS-14, a novel ADAMTS displaying high homology with ADAMTS-2 and ADAMTS-3. J Biol Chem 2002; 277: 5756-66.
19. Colige A, Ruggiero F, Vandenberghe I, et al. Domains and maturation processes that regulate the activity of ADAMTS-2, a metalloproteinase cleaving the aminopropeptide of fibrillar procollagens types I-III and V. J Biol Chem 2005; 280: 34397-408.
20. Fernandes R, Hirohata S, Engle J, et al. Procollagen II amino propeptide processing by ADAMTS-3. Insights on dermatosparaxis. J Biol Chem 2001; 276: 31502-9.
21. Kutz WE, Wang LW, Bader HL, et al. ADAMTS10 protein interacts with fibrillin-1 and promotes its deposition in extracellular matrix of cultured fibroblasts. J Biol Chem 2011; 286: 17156-67.
22. Morales J, Al-Sharif L, Khalil D, et al. Homozygous mutations in ADAMTS10 and ADAMTS17 cause lenticular myopia, ectopia lentis, glaucoma, spherophakia, and short stature. Am J Hum Genet 2009; 85: 558-68.
23. Russell DL, Doyle KM, Ochsner SA, et al. Processing and localization of ADAMTS-1 and proteolytic cleavage of versican during cumulus matrix expansion and ovulation. J Biol Chem 2003; 278: 42330-9.
24. Held-Feindt J, Paredes EB, Blomer U, et al. Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomas. Int J Cancer 2006; 118: 55-61.
25. Kenagy RD, Min SK, Clowes AW, et al. Cell death-associated ADAMTS4 and versican degradation in vascular tissue. J Histochem Cytochem 2009; 57: 889-97.
26. Didangelos A, Mayr U, Monaco C, et al. Novel role of ADAMTS-5 protein in proteoglycan turnover and lipoprotein retention in atherosclerosis. J Biol Chem 2012; 287: 19341-5.
27. Luan Y, Kong L, Howell D, et al. Inhibition of ADAMTS-7 and ADAMTS-12 degradation of cartilage oligomeric matrix protein by alpha-2-macroglobulin. Osteoarthritis Cartilage 2008; 16: 1413-20.
28. Enomoto H, Nelson C, Somerville R, et al. Cooperation of two ADAMTS metalloproteases in closure of the mouse palate identifies a requirement for versican proteolysis in regulating palatal mesenchyme proliferation. Development 2010; 137: 4029-38.
29. Liu C-j, Kong W, Xu K, et al. ADAMTS-12 associates with and degrades cartilage oligomeric matrix protein. J Biol Chem 2006; 281: 15800-8.
30. Peluffo MC, Murphy MJ, Baughman ST, et al. Systematic analysis of protease gene expression in the rhesus macaque ovulatory follicle: metalloproteinase involvement in follicle rupture. Endocrinology 2011; 152: 3963-74.
31. Gao S, De Geyter C, Kossowska K, et al. FSH stimulates the expression of the ADAMTS-16 protease in mature human ovarian follicles. Mol Hum Reprod 2007; 13: 465-71.
32. Li Z, Zhang W, Shao Y, et al. High-resolution melting analysis of ADAMTS18 methylation levels in gastric, colorectal and pancreatic cancers. Med Oncol 2010; 27: 998-1004.
33. Wagstaff L, Kelwick R, Decock J, et al. The roles of ADAMTS metalloproteinases in tumorigenesis and metastasis. Front Biosci 2011; 16: 1861-72.
34. Kuno K, Kanada N, Nakashima E, et al. Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene. J Biol Chem 1997; 272: 556-62.
35. Thai SN, Iruela-Arispe ML,. Expression of ADAMTS1 during murine development. Mech Dev 2002; 115: 181-5.
36. Shindo T, Kurihara H, Kuno K, et al. ADAMTS-1: a metalloproteinase- disintegrin essential for normal growth, fertility, and organ morphology and function. J Clin Invest 2000; 105: 1345-52.
37. Mittaz L, Russell DL, Wilson T, et al. Adamts-1 is essential for the development and function of the urogenital system. Biol Reprod 2004; 70: 1096-105.
38. Gunther W, Skaftnesmo KO, Arnold H, et al. Distribution patterns of the anti-angiogenic protein ADAMTS-1 during rat development. Acta Histochem 2005; 107: 121-31.
39. Brown HM, Dunning KR, Robker RL, et al. Requirement for ADAMTS-1 in extracellular matrix remodeling during ovarian folliculogenesis and lymphangiogenesis. Dev Biol 2006; 300: 699-709.
40. Brown HM, Robker RL, Russell DL,. Development and hormonal regulation of the ovarian lymphatic vasculature. Endocrinology 2010; 151: 5446-55.
41. Iruela-Arispe ML, Carpizo D, Luque A,. ADAMTS1: a matrix metalloprotease with angioinhibitory properties. Ann N Y Acad Sci 2003; 995: 183-90.
42. Krampert M, Kuenzle S, Thai SN, et al. ADAMTS1 proteinase is up-regulated in wounded skin and regulates migration of fibroblasts and endothelial cells. J Biol Chem 2005; 280: 23844-52.
43. Lee NV, Sato M, Annis DS, et al. ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. EMBO J 2006; 25: 5270-83.
44. Misra S, Lee N, Fu AA, et al. Increased expression of a disintegrin and metalloproteinase thrombospondin 1 in thrombosed hemodialysis grafts. J Vasc Interv Radiol 2008; 19: 111-9.
45. Luque A, Carpizo DR, Iruela-Arispe ML,. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J Biol Chem 2003; 278: 23656-65.
46. Brown HM, Dunning KR, Robker RL, et al. ADAMTS1 cleavage of versican mediates essential structural remodeling of the ovarian follicle and cumulus-oocyte matrix during ovulation in mice. Biol Reprod 2010; 83: 549-57.
47. Nakamura M, Sone S, Takahashi I, et al. Expression of versican and ADAMTS1, 4, and 5 during bone development in the rat mandible and hind limb. J Histochem Cytochem 2005; 53: 1553-62.
48. Rodriguez-Manzaneque JC, Carpizo D, Plaza-Calonge Mdel C, et al. Cleavage of syndecan-4 by ADAMTS1 provokes defects in adhesion. Int J Biochem Cell Biol 2009; 41: 800-10.
49. Kuno K, Okada Y, Kawashima H, et al. ADAMTS-1 cleaves a cartilage proteoglycan, aggrecan. FEBS Lett 2000; 478: 241-5.
50. Sandy JD, Westling J, Kenagy RD, et al. Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. J Biol Chem 2001; 276: 13372-8.
51. Rehn AP, Birch MA, Karlstrom E, et al. ADAMTS-1 increases the three-dimensional growth of osteoblasts through type I collagen processing. Bone 2007; 41: 231-8.
52. Hu L, Jonsson KB, Andersen H, et al. Over-expression of Adamts1 in mice alters bone mineral density. J Bone Miner Metabol 2012; 30: 304-11.
53. Lind T, Birch MA, McKie N,. Purification of an insect derived recombinant human ADAMTS-1 reveals novel gelatin (type I collagen) degrading activities. Mol Cell Biochem 2006; 281: 95-102.
54. Zreiqat H, Belluoccio D, Smith MM, et al. S100A8 and S100A9 in experimental osteoarthritis. Arthritis Res Ther 2010; 12: R16.
55. Wachsmuth L, Bau B, Fan Z, et al. ADAMTS-1, a gene product of articular chondrocytes in vivo and in vitro, is downregulated by interleukin 1beta. J Rheumatol 2004; 31: 315-20.
56. Stankunas K, Hang C, Tsun Z-Y, et al. Endocardial Brg1 represses ADAMTS1 to maintain the microenvironment for myocardial morphogenesis. Dev Cell 2008; 14: 298-609.
57. Reynolds LE, Watson AR, Baker M, et al. Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature 2010; 465: 813-7.
58. Yatabe T, Mochizuki S, Takizawa M, et al. Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes. Ann Rheum Dis 2009; 68: 1051-8.
59. Misra S, Shergill U, Yang B, et al. Increased expression of HIF-1alpha, VEGF-A and its receptors, MMP-2, TIMP-1, and ADAMTS-1 at the venous stenosis of arteriovenous fistula in a mouse model with renal insufficiency. J Vasc Interv Radiol 2010; 21: 1255-61.
60. Fu Y, Nagy JA, Brown LF, et al. Proteolytic cleavage of versican and involvement of ADAMTS-1 in VEGF-A/VPF-induced pathological angiogenesis. J Histochem Cytochem 2011; 59: 463-73.
61. Gustavsson H, Jennbacken K, Welen K, et al. Altered expression of genes regulating angiogenesis in experimental androgen-independent prostate cancer. Prostate 2008; 68: 161-70.
62. Gustavsson H, Wang W, Jennbacken K, et al. ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancer. BJU Int 2009; 104: 1786-90.
63. Kuno K, Bannai K, Hakozaki M, et al. The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential. Biochem Biophys Res Commun 2004; 319: 1327-33.
64. Lind GE, Kleivi K, Meling GI, et al. ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol 2006; 28: 259-72.
65. Liu YJ, Xu Y, Yu Q,. Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. Oncogene 2006; 25: 2452-67.
66. Masui T, Hosotani R, Tsuji S, et al. Expression of METH-1 and METH-2 in pancreatic cancer. Clin Cancer Res 2001; 7: 3437-43.
67. Rocks N, Paulissen G, Quesada-Calvo F, et al. ADAMTS-1 metalloproteinase promotes tumor development through the induction of a stromal reaction in vivo. Cancer Res 2008; 68: 9541-50.
68. Bonuccelli G, Casimiro MC, Sotgia F, et al. Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature. Am J Pathol 2009; 174: 1650-62.
69. Hirano T, Hirose K, Sakurai K, et al. Inhibition of tumor growth by antibody to ADAMTS1 in mouse xenografts of breast cancer. Anticancer Res 2011; 31: 3839-42.
70. Tyan SW, Hsu CH, Peng KL, et al. Breast cancer cells induce stromal fibroblasts to secrete ADAMTS1 for cancer invasion through an epigenetic change. PloS One 2012; 7: e35128.
71. Choi JE, Kim DS, Kim EJ, et al. Aberrant methylation of ADAMTS1 in non-small cell lung cancer. Cancer Genet Cytogenet 2008; 187: 80-4.
72. Kohno T, Otsuka A, Girard L, et al. A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer 2010; 49: 342-52.
73. Ifon ET, Pang AL, Johnson W, et al. U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3. Cancer Cell Int 2005; 5: 19.
74. Yegnasubramanian S, Wu Z, Haffner MC, et al. Chromosome-wide mapping of DNA methylation patterns in normal and malignant prostate cells reveals pervasive methylation of gene-associated and conserved intergenic sequences. BMC Genom 2011; 12: 313.
75. Gustavsson H, Tesan T, Jennbacken K, et al. ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors. BMC Cancer 2010; 10: 288.
76. Kuno K, Terashima Y, Matsushima K,. ADAMTS-1 is an active metalloproteinase associated with the extracellular matrix. J Biol Chem 1999; 274: 18821-6.
77. Lee NV, Rodriguez-Manzaneque JC, Thai SN, et al. Fibulin-1 acts as a cofactor for the matrix metalloprotease ADAMTS-1. J Biol Chem 2005; 280: 34796-804.
78. Bourd-Boittin K, Bonnier D, Leyme A, et al. Protease profiling of liver fibrosis reveals the ADAM metallopeptidase with thrombospondin type 1 motif, 1 as a central activator of transforming growth factor beta. Hepatology 2011; 54: 2173-84.
79. Rodriguez-Manzaneque JC, Westling J, Thai SN, et al. ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem Biophys Res Commun 2002; 293: 501-8.
80. Canals F, Colome N, Ferrer C, et al. Identification of substrates of the extracellular protease ADAMTS1 by DIGE proteomic analysis. Proteomics 2006; 6 Suppl 1: S28-S35.
81. Kilpinen S, Autio R, Ojala K, et al. Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biol 2008; 9: R139.
82. Kilpinen S, Ojala K, Kallioniemi O,. Alignment of gene expression profiles from test samples against a reference database: new method for context-specific interpretation of microarray data. BioData mining 2011; 4: 5.
83. Ahlquist T, Lind GE, Costa VL, et al. Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer 2008; 7: 94.
84. Leslie A, Carey FA, Pratt NR, et al. The colorectal adenoma-carcinoma sequence. Br J Surg 2002; 89: 845-60.
85. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8: 393-406.
86. Best C, Gillespie J, Yi Y, et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005; 11: 6823-34.
87. Wurmbach E, Chen Y-B, Khitrov G, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007; 45: 938-47.
88. Mas V, Maluf D, Archer K, et al. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med 2009; 15: 85-94.
89. Porter S, Scott S, Sassoon E, et al. Dysregulated expression of adamalysin-thrombospondin genes in human breast carcinoma. Clin Cancer Res 2004; 10: 2429-69.
90. Culig Z, Bartsch G,. Androgen axis in prostate cancer. J Cell Biochem 2006; 99: 373-81.
91. Navarro D, Luzardo OP, Fernandez L, et al. Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol 2002; 81: 191-201.
92. Mellado B, Codony J, Ribal MJ, et al. Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway. Clin Transl Oncol 2009; 11: 5-10.
93. Devlin HL, Mudryj M,. Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 2009; 274: 177-86.
94. Shore N, Mason M, de Reijke T,. New developments in castrate-resistant prostate cancer. BJU Int 2012; 109 Suppl 6: 22-32.
95. Jennbacken K, Gustavsson H, Tesan T, et al. The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: an effect influenced by testosterone. Prostate 2009; 69: 1164-75.
96. Marques R, Erkens-Schulze S, de Ridder C, et al. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment. Int J Cancer 2005; 117: 221-9.
97. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401-6.
98. Edwards J, Krishna N, Grigor K, et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003; 89: 552-6.
99. Decker KF, Zheng D, He Y, et al. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res 2012; 40: 10765-79.
100. Danielpour D,. Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. Eur J Cancer 2005; 41: 846-57.
101. Russell P, Bennett S,. Growth factor involvement in progression of prostate cancer. Clin Chem 1998.
102. Aitchison A, Veerakumarasivam A, Vias M, et al. Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. Prostate 2008; 68: 661-74.
103. Tewari A, Yardimci G, Shibata Y, et al. Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity. Genome Biol 2012; 13.
104. Friedlander T, Roy R, Tomlins S, et al. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res 2012; 72: 616-25.
105. Braconi C, Meng F, Swenson E, et al. Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures. Cancer 2009; 115: 3738-48.
106. Chen X, Cheung ST, So S, et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002; 13: 1929-39.
107. Schwettmann L, Wehmeier M, Jokovic D, et al. Hepatic expression of A disintegrin and metalloproteinase (ADAM) and ADAMs with thrombospondin motives (ADAM-TS) enzymes in patients with chronic liver diseases. J Hepatol 2008; 49: 243-50.
108. Desjardins LA,. Hepatocellular carcinoma. Clin J Oncol Nurs 2002; 6: 107-8.
109. Srivatanakul P, Sriplung H, Deerasamee S,. Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev 2004; 5: 118-25.
110. Hayashi PH, Di Bisceglie AM,. The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: epidemiology and pathogenesis. Med Clin North Am 2005; 89: 371-89.
111. Starr SP, Raines D,. Cirrhosis: diagnosis, management, and prevention. Am Fam Phys 2011; 84: 1353-9.
112. Neubauer K, Saile B, Ramadori G,. Liver fibrosis and altered matrix synthesis. Can J Gastroenterol 2001; 15: 187-93.
113. Hayashi H, Sakai T,. Biological significance of Local TGF-beta activation in liver diseases. Front Physiol 2012; 3: 12.
114. Zi Z, Chapnick D, Liu X,. Dynamics of TGF-β/Smad signaling. FEBS Lett 2012; 586: 1921-8.
115. Li T, Sotgia F, Vuolo M, et al. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor α-positive status. Am J Pathol 2006; 168: 1998-2013.
116. Chen J, Zhi Y, Chang X, et al. Expression of ADAMTS1 and Its Correlation With Angiogenesis In Primary Gastric Cancer And Lymph Node Metastasis. Digest Dis Sci 2013; 58: 405-13.
117. Casimiro S, Luis I, Fernandes A, et al. Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors. Clin Exp Metastasis 2012; 29: 155-64.
118. Kang Y, Siegel P, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537-49.
119. Lu X, Wang Q, Hu G, et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 2009; 23: 1882-94.
120. Minn AJ, Kang Y, Serganova I, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005; 115: 44-55.
121. Rodriguez-Manzaneque JC, Milchanowski AB, Dufour EK, et al. Characterization of METH-1/ADAMTS1 processing reveals two distinct active forms. J Biol Chem 2000; 275: 33471-9.
122. Obika M, Ogawa H, Takahashi K, et al. Tumor growth inhibitory effect of ADAMTS1 is accompanied by the inhibition of tumor angiogenesis. Cancer Sci 2012; 103: 1889-97.
123. Lee YJ, Koch M, Karl D, et al. Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1. Cancer Res 2010; 70: 948-56.
124. Keightley MC, Sales KJ, Jabbour HN,. PGF2alpha-F-prostanoid receptor signalling via ADAMTS1 modulates epithelial cell invasion and endothelial cell function in endometrial cancer. BMC Cancer 2010; 10: 488.
125. Steiner I, Jung K, Miller K, et al. Expression of endothelial factors in prostate cancer: a possible role of caveolin-1 for tumour progression. Oncol Rep 2012; 27: 389-95.
126. Grigo K, Wirsing A, Lucas B, et al. HNF4 alpha orchestrates a set of 14 genes to down-regulate cell proliferation in kidney cells. Biol Chem 2008; 389: 179-87.
127. Esselens C, Malapeira J, Colome N, et al. The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration. J Biol Chem 2010; 285: 2463-73.
128. Vazquez F, Hastings G, Ortega MA, et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 1999; 274: 23349-57.
129. Iruela-Arispe ML, Lombardo M, Krutzsch HC, et al. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 1999; 100: 1423-31.
130. Dawson D, Pearce S, Zhong R, et al. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997; 138: 707-17.
131. Ryeom S, Folkman J,. Role of endogenous angiogenesis inhibitors in Down syndrome. J Raniofac Surg 2009; 20 Suppl 1: 595-6.
132. Basile DP, Fredrich K, Chelladurai B, et al. Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1, a novel VEGF inhibitor. Am J Physiol Renal Physiol 2008; 294: F928-F36.
133. Rocks N, Paulissen G, et al. Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). Br J Cancer 2006; 94: 724-30.
134. Borre M, Offersen BV, Nerstrom B, et al. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998; 78: 940-4.
135. Mydlo JH, Kral JG, Volpe M, et al. An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer. preliminary results and therapeutic implications. Eur Urol 1998; 34: 426-32.
136. Offersen BV, Borre M, Overgaard J,. Immunohistochemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer. APMIS 1998; 106: 463-9.
137. Offersen BV, Borre M, Overgaard J,. Quantification of angiogenesis as a prognostic marker in human carcinomas: a critical evaluation of histopathological methods for estimation of vascular density. Eur J Cancer 2003; 39: 881-90.
138. Siegal JA, Yu E, Brawer MK,. Topography of neovascularity in human prostate carcinoma. Cancer 1995; 75: 2545-51.
139. Strohmeyer D, Rossing C, Bauerfeind A, et al. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000; 45: 216-24.
140. Tomic TT, Gustavsson H, Wang W, et al. Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2. Prostate 2012; 72: 705-12.
141. Lind AJ, Wikstrom P, Granfors T, et al. Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate 2005; 62: 394-9.
142. Morrissey C, True LD, Roudier MP, et al. Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis 2008; 25: 377-88.
143. Winter SF, Acevedo VD, Gangula RD, et al. Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2. Oncogene 2007; 26: 4897-907.
144. Lebaron RG,. Versican. Perspectives on developmental neurobiology 1996; 3: 261-71.
145. LeBaron RG, Zimmermann DR, Ruoslahti E,. Hyaluronate binding properties of versican. J Biol Chem 1992; 267: 10003-10.
146. Ricciardelli C, Sakko AJ, Ween MP, et al. The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev 2009; 28: 233-45.
147. Yang BL, Zhang Y, Cao L, et al. Cell adhesion and proliferation mediated through the G1 domain of versican. J Cell Biochem 1999; 72: 210-20.
148. Zhang Y, Cao L, Kiani C, et al. Promotion of chondrocyte proliferation by versican mediated by G1 domain and EGF-like motifs. J Cell Biochem 1999; 73: 445-57.
149. Zhang Y, Cao L, Kiani CG, et al. The G3 domain of versican inhibits mesenchymal chondrogenesis via the epidermal growth factor-like motifs. J Biol Chem 1998; 273: 33054-63.
150. Wu Y, Chen L, Cao L, et al. Overexpression of the C-terminal PG-M/versican domain impairs growth of tumor cells by intervening in the interaction between epidermal growth factor receptor and beta1-integrin. J Cell Sci 2004; 117: 2227-37.
151. Zheng PS, Wen J, Ang LC, et al. Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J 2004; 18: 754-6.
152. Yu J, Ren X, Cao S, et al. Th1 polarization and apoptosis-inducing activity of CD4+ T -cells in cytokine-induced killers might favor the antitumor cytotoxicity of cytokine-induced killers in vivo. Cancer Biother Radiopharm 2006; 21: 276-84.
153. Zhang X, Brunner T, Carter L, et al. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 1997; 185: 1837-49.
154. Kim S, Takahashi H, Lin WW, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457: 102-6.
155. Wang W, Xu GL, Jia WD, et al. Ligation of TLR2 by versican: a link between inflammation and metastasis. Arch Med Res 2009; 40: 321-3.
156. Cattaruzza S, Schiappacassi M, Kimata K, et al. The globular domains of PG-M/versican modulate the proliferation-apoptosis equilibrium and invasive capabilities of tumor cells. FASEB J 2004; 18: 779-81.
157. Sheng W, Wang G, Wang Y, et al. The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol Biol Cell 2005; 16: 1330-40.
158. De Giorgi F, Lartigue L, Bauer M, et al. The permeability transition pore signals apoptosis by directing Bax translocation and multimerization. FASEB J 2002; 16: 607-9.
159. Altemeier WA, Schlesinger SY, Buell CA, et al. Transmembrane and extracellular domains of syndecan-1 have distinct functions in regulating lung epithelial migration and adhesion. J Biol Chem 2012; 287: 34927-35.
160. Altemeier WA, Schlesinger SY, Buell CA, et al. Syndecan-1 controls cell migration by activating Rap1 to regulate focal adhesion disassembly. J Cell Sci 2012.
161. Okina E, Grossi A, Gopal S, et al. Alpha-actinin interactions with syndecan-4 are integral to fibroblast-matrix adhesion and regulate cytoskeletal architecture. Int J Biochem Cell Biol 2012; 44: 2161-74.
162. Zong F, Fthenou E, Mundt F, et al. Specific syndecan-1 domains regulate mesenchymal tumor cell adhesion, motility and migration. PloS One 2011; 6: e14816.
163. Ricciardelli C, Russell DL, Ween MP, et al. Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem 2007; 282: 10814-25.
164. Ween MP, Hummitzsch K, Rodgers RJ, et al. Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides. Clin Exp Metastasis 2011; 28: 113-25.